BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22185567)

  • 1. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy.
    Zhang G; Shang B; Yang P; Cao Z; Pan Y; Zhou Q
    Stem Cells Dev; 2012 Apr; 21(6):955-64. PubMed ID: 22185567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.
    Griscelli F; Féraud O; Oudrhiri N; Gobbo E; Casal I; Chomel JC; Biéche I; Duvillard P; Opolon P; Turhan AG; Bennaceur-Griscelli A
    Am J Pathol; 2012 May; 180(5):2084-96. PubMed ID: 22425713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency.
    Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G
    Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of human pluripotent stem cells to retinal pigmented epithelium in defined conditions using purified extracellular matrix proteins.
    Rowland TJ; Blaschke AJ; Buchholz DE; Hikita ST; Johnson LV; Clegg DO
    J Tissue Eng Regen Med; 2013 Aug; 7(8):642-53. PubMed ID: 22514096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging in the mouse and perspectives of rejuvenation through induced pluripotent stem cells (iPSCs).
    Isobe K; Cheng Z; Ito S; Nishio N
    Results Probl Cell Differ; 2012; 55():413-27. PubMed ID: 22918818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotency and oncogenic transformation are related processes.
    Riggs JW; Barrilleaux BL; Varlakhanova N; Bush KM; Chan V; Knoepfler PS
    Stem Cells Dev; 2013 Jan; 22(1):37-50. PubMed ID: 22998387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells.
    Mosca E; Cocola C; Sabour D; Pelucchi P; Bertalot G; Palumbo O; Carella M; Götte M; Schöler HR; Reinbold R; Zucchi I; Milanesi L
    In Silico Biol; 2010; 10(5-6):207-21. PubMed ID: 22430355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model.
    Chien Y; Chang YL; Li HY; Larsson M; Wu WW; Chien CS; Wang CY; Chu PY; Chen KH; Lo WL; Chiou SH; Lan YT; Huo TI; Lee SD; Huang PI
    Acta Biomater; 2015 Feb; 13():228-44. PubMed ID: 25463491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.
    Yamashita A; Liu S; Woltjen K; Thomas B; Meng G; Hotta A; Takahashi K; Ellis J; Yamanaka S; Rancourt DE
    Sci Rep; 2013; 3():1978. PubMed ID: 23760219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.
    Jia B; Chen S; Zhao Z; Liu P; Cai J; Qin D; Du J; Wu C; Chen Q; Cai X; Zhang H; Yu Y; Pei D; Zhong M; Pan G
    Life Sci; 2014 Jul; 108(1):22-9. PubMed ID: 24834837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts.
    Sasaki H; Wada H; Baghdadi M; Tsuji H; Otsuka R; Morita K; Shinohara N; Seino K
    Transplantation; 2015 Nov; 99(11):2301-10. PubMed ID: 26360665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.
    Itakura G; Kawabata S; Ando M; Nishiyama Y; Sugai K; Ozaki M; Iida T; Ookubo T; Kojima K; Kashiwagi R; Yasutake K; Nakauchi H; Miyoshi H; Nagoshi N; Kohyama J; Iwanami A; Matsumoto M; Nakamura M; Okano H
    Stem Cell Reports; 2017 Mar; 8(3):673-684. PubMed ID: 28262544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumourigenicity of iPS cells and their differentiated derivates.
    Liu Z; Tang Y; Lü S; Zhou J; Du Z; Duan C; Li Z; Wang C
    J Cell Mol Med; 2013 Jun; 17(6):782-91. PubMed ID: 23711115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.
    Sougawa N; Miyagawa S; Fukushima S; Kawamura A; Yokoyama J; Ito E; Harada A; Okimoto K; Mochizuki-Oda N; Saito A; Sawa Y
    Sci Rep; 2018 Feb; 8(1):3726. PubMed ID: 29487310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
    Chehelgerdi M; Behdarvand Dehkordi F; Chehelgerdi M; Kabiri H; Salehian-Dehkordi H; Abdolvand M; Salmanizadeh S; Rashidi M; Niazmand A; Ahmadi S; Feizbakhshan S; Kabiri S; Vatandoost N; Ranjbarnejad T
    Mol Cancer; 2023 Nov; 22(1):189. PubMed ID: 38017433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological classification of human iPSC-derived neural stem/progenitor cells towards safety assessment of transplantation therapy for CNS diseases.
    Sugai K; Fukuzawa R; Shofuda T; Fukusumi H; Kawabata S; Nishiyama Y; Higuchi Y; Kawai K; Isoda M; Kanematsu D; Hashimoto-Tamaoki T; Kohyama J; Iwanami A; Suemizu H; Ikeda E; Matsumoto M; Kanemura Y; Nakamura M; Okano H
    Mol Brain; 2016 Sep; 9(1):85. PubMed ID: 27642008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Road to future: iPSC clinical application in Parkinson's disease treatment.
    Xu L; Tan YY; Wu L; Wang LL; Li H; Ding JQ; Chen SD
    Curr Mol Med; 2013 Nov; 13(9):1412-8. PubMed ID: 23971738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. iPSCs, aging and age-related diseases.
    Isobe K; Cheng Z; Nishio N; Suganya T; Tanaka Y; Ito S
    N Biotechnol; 2014 Sep; 31(5):411-21. PubMed ID: 24784583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient.
    Tubsuwan A; Abed S; Deichmann A; Kardel MD; Bartholomä C; Cheung A; Negre O; Kadri Z; Fucharoen S; von Kalle C; Payen E; Chrétien S; Schmidt M; Eaves CJ; Leboulch P; Maouche-Chrétien L
    Stem Cells; 2013 Sep; 31(9):1785-94. PubMed ID: 23712774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.